Search results
Showing 7426 to 7440 of 7674 results
In development [GID-TA11089] Expected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
In development [GID-TA11411] Expected publication date: TBC
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
This guidance has been updated and replaced by NICE technology appraisal guidance 988.
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]
In development [GID-TA11580] Expected publication date: TBC
In development [GID-TA10745] Expected publication date: 17 July 2024
In development [GID-TA11567] Expected publication date: TBC
In development [GID-TA11482] Expected publication date: TBC
In development [GID-TA11475] Expected publication date: TBC
In development [GID-TA11301] Expected publication date: TBC
June 2023: We are aware that the International Journal of Gynecology and Obstetrics has retracted a 2016 paper, which was used in committee decision making for this topic (IPG744). As the evidence base has now changed, it is returning to committee for re-discussion, see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. Once the schedule for this has been confirmed, it will be communicated to stakeholders and published on the NICE website. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development [GID-TA11353] Expected publication date: TBC
In development [GID-TA11582] Expected publication date: TBC
September 2024: We have withdrawn this guidance. This is because the main evidence that the guidance was based on has been retracted by the journal. New NICE interventional procedures guidance is in development and the expected publication date is April 2025. Please see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.
This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.